Free Trial
NASDAQ:RVNC

Revance Therapeutics (RVNC) Stock Price, News & Analysis

Revance Therapeutics logo
$3.65 0.00 (0.00%)
As of 02/6/2025

About Revance Therapeutics Stock (NASDAQ:RVNC)

Key Stats

Today's Range
$3.65
$3.65
50-Day Range
$3.65
$3.65
52-Week Range
$2.30
$6.65
Volume
N/A
Average Volume
3.28 million shs
Market Capitalization
$381.02 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.39
Consensus Rating
Hold

Company Overview

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Revance Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
50th Percentile Overall Score

RVNC MarketRank™: 

Revance Therapeutics scored higher than 50% of companies evaluated by MarketBeat, and ranked 681st out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Revance Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.11, and is based on 1 buy rating, 8 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Revance Therapeutics has received no research coverage in the past 90 days.

  • Read more about Revance Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Revance Therapeutics are expected to grow in the coming year, from ($1.57) to ($1.08) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Revance Therapeutics is -1.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Revance Therapeutics is -1.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Revance Therapeutics' valuation and earnings.
  • Short Interest

    There is no current short interest data available for RVNC.
  • Dividend Yield

    Revance Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Revance Therapeutics does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for RVNC.
    • Insider Buying vs. Insider Selling

      In the past three months, Revance Therapeutics insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      Only 5.10% of the stock of Revance Therapeutics is held by insiders.

    • Percentage Held by Institutions

      97.70% of the stock of Revance Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

    • Read more about Revance Therapeutics' insider trading history.
    Receive RVNC Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Revance Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

    RVNC Stock News Headlines

    Crown Laboratories Now Operates Under the Name Revance
    Here’s How to Claim Your Stake in Elon’s Private Company, xAI
    I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.
    See More Headlines

    RVNC Stock Analysis - Frequently Asked Questions

    Revance Therapeutics' stock was trading at $3.04 on January 1st, 2025. Since then, RVNC shares have increased by 20.1% and is now trading at $3.65.
    View the best growth stocks for 2025 here
    .

    Revance Therapeutics, Inc. (NASDAQ:RVNC) released its quarterly earnings results on Thursday, August, 8th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.48) by $0.12. The firm's revenue was up 20.2% compared to the same quarter last year.
    Read the conference call transcript
    .

    Shares of RVNC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Based on aggregate information from My MarketBeat watchlists, some other companies that Revance Therapeutics investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Advanced Micro Devices (AMD), Netflix (NFLX) and Home Depot (HD).

    Company Calendar

    Last Earnings
    8/08/2024
    Today
    5/04/2025
    Next Earnings (Estimated)
    5/07/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Sector
    Medical
    Industry
    Pharmaceutical preparations
    Sub-Industry
    Pharmaceutical Products
    Current Symbol
    NASDAQ:RVNC
    Employees
    500
    Year Founded
    N/A

    Price Target and Rating

    Average Stock Price Target
    $8.39
    High Stock Price Target
    $20.00
    Low Stock Price Target
    $3.00
    Potential Upside/Downside
    +129.7%
    Consensus Rating
    Hold
    Rating Score (0-4)
    2.11
    Research Coverage
    9 Analysts

    Profitability

    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    $-323,990,000.00
    Pretax Margin
    -122.07%

    Debt

    Sales & Book Value

    Annual Sales
    $234.04 million
    Price / Cash Flow
    N/A
    Book Value
    ($1.73) per share
    Price / Book
    -2.11

    Miscellaneous

    Free Float
    99,066,000
    Market Cap
    $381.02 million
    Optionable
    Optionable
    Beta
    0.90

    Social Links

    These 7 Stocks Will Be Magnificent in 2025 Cover

    Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

    Get This Free Report

    This page (NASDAQ:RVNC) was last updated on 5/4/2025 by MarketBeat.com Staff
    From Our Partners